Related Experiment Video

Updated: May 20, 2025

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

51.9K

Imidazole-Based ALK5 Inhibitor Attenuates TGF-β/Smad-Mediated Hepatic Stellate Cell Activation and Hepatic

Si-Qi Wang1,2, Yu-Qing Meng1,2, Yan-Ling Wu1,2

  • 1Key Laboratory of Traditional Chinese Korean Medicine Research (Yanbian University) of State Ethnic Affairs Commission, College of Pharmacy, Yanbian University, Yanji, Jilin Province 133002, China.

Chemical Research in Toxicology
|April 11, 2025
PubMed

Insights

The novel compound J-1149 effectively combats liver fibrosis by inhibiting the TGF-β/Smad pathway and reducing inflammation. This imidazole derivative shows promise as a new therapeutic for liver damage.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hepatology

Background:

  • Liver fibrosis is a significant clinical challenge with limited treatment options.
  • Transforming growth factor-beta (TGF-β) signaling, particularly ALK5 phosphorylation, is central to liver fibrosis.
  • Targeting ALK5 signal transduction presents a promising therapeutic avenue for liver fibrosis.

Purpose of the Study:

  • To synthesize and evaluate the antifibrotic potential of the imidazole derivative J-1149.
  • To elucidate the mechanisms by which J-1149 exerts its antifibrotic effects.
  • To assess J-1149's impact on key fibrotic pathways and inflammatory responses.

Main Methods:

  • Synthesis of the imidazole derivative J-1149 with inhibitory activity against ALK5.
  • Investigation of J-1149's effects on the TGF-β/Smad signaling pathway in hepatic stellate cells (HSCs).
  • Evaluation of J-1149's influence on the P2X7R/NLRP3 inflammasome axis and immune cell infiltration.

Main Results:

  • J-1149 significantly attenuated HSC activation and liver fibrogenesis.
  • The compound acts by modulating the TGF-β/Smad signaling pathway.
  • J-1149 was found to impede the P2X7R/NLRP3 axis, reduce immune cell infiltration, and decrease liver fibrogenesis.

Conclusions:

  • J-1149 demonstrates significant antifibrotic activity through multiple mechanisms.
  • The compound effectively targets key pathways involved in liver fibrosis progression.
  • J-1149 represents a promising therapeutic candidate for treating liver fibrosis.

More Related Videos

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.1K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

18.7K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
119
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146